4Naglazyme – Price: $365.000
The Maroteaux–Lamy syndrome was an untreatable, sever type of dwarfism until BioMarin created Naglazym.
Priced at $365.000, the drug was first tested in clinical trials and it successfully improved the natural growth of the body.
The treatment can result in easier walking and stair-climbing.
The price of the drug is based on the age of the patient but it will still be lower than other expensive drugs, because the patients are usually young.
